HOTAIR in colorectal cancer: structure, function, and therapeutic potential

Tufail, Muhammad

doi:10.1007/s12032-023-02131-5

Cited by 4 publications

(2 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The deregulation of HOTAIR is strongly related to cancer development and progression (Table 1) (Zhang et al, 2014;Liguori et al, 2021;Xin et al, 2021;Qu et al, 2023;Tufail, 2023;Zhou et al, 2023;Hakami et al, 2024).…”

Section: The Role Of Hotair In Cancermentioning

confidence: 99%

The role of HOTAIR in the modulation of resistance to anticancer therapy

Cantile,

Belli,

Scognamiglio

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

Leading anti-tumour therapeutic strategies typically involve surgery and radiotherapy for locally advanced (non-metastatic) cancers, while hormone therapy, chemotherapy, and molecular targeted therapy are the current treatment options for metastatic cancer. Despite the initially high sensitivity rate to anticancer therapies, a large number of patients develop resistance, leading to a poor prognosis. The mechanisms related to drug resistance are highly complex, and long non-coding RNAs appear to play a crucial role in these processes. Among these, the lncRNA homeobox transcript antisense intergenic RNA (HOTAIR), widely implicated in cancer initiation and progression, likewise plays a significant role in anticancer drug resistance. It can modulate cell activities such as proliferation, apoptosis, hypoxia, autophagy, as well as epithelial-mesenchymal transition, thereby contributing to the development of resistant tumour cells. In this manuscript, we describe different mechanisms of antitumor drug resistance in which HOTAIR is involved and suggest its potential as a therapeutic predictive biomarker for the management of cancer patients.

show abstract

Section: The Role Of Hotair In Cancermentioning

confidence: 99%

The role of HOTAIR in the modulation of resistance to anticancer therapy

Cantile,

Belli,

Scognamiglio

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…Several studies reported that certain lncRNAs contribute to the progression of colorectal cancer, such as HOTAIR, MALAT-1, and CCAT1/CCAT2 [ 7 , 8 , 9 , 10 ]. HOTAIR expression is increased in colorectal cancers and is associated with metastasis and poor prognosis [ 11 , 12 , 13 , 14 , 15 ]. Similarly, MALAT-1 is also upregulated in colorectal cancers and promotes the proliferation of colorectal cancer cells [ 16 , 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Long Noncoding RNA RP11-278A23.1, a Potential Modulator of p53 Tumor Suppression, Contributes to Colorectal Cancer Progression

Kamikokura,

Tange,

Nakase

et al. 2024

Cancers

View full text Add to dashboard Cite

Recently, many studies revealed that long noncoding RNAs (lncRNAs) play important roles in cancers. To identify lncRNAs contributing to colorectal cancers, we screened lncRNAs through expression and survival analyses in datasets from The Cancer Genome Atlas (TCGA). The screen revealed that RP11-278A23.1 expression is significantly increased in colorectal cancer tissues compared with normal tissues and that high RP11-278A23.1 expression correlates with poor prognosis. The knockdown of RP11-278A23.1 inhibited the growth of and promoted apoptosis in colorectal cancer cells. Next, to comprehensively examine differentially expressed genes after RP11-278A23.1 knockdown, RNA sequencing was performed in HCT116 cells. The expression of p21, a p53 target gene, was significantly upregulated, and the expression of several p53 target proapoptotic genes was also altered. RP11-278A23.1 knockdown increased p53 expression at the translational level but not at the transcriptional level. Interestingly, RP11-278A23.1 knockdown also altered the expression of these proapoptotic genes in DLD1 cells with mutated p53 and in p53-knockout HCT116 cells. These results suggest that RP11-278A23.1 modifies the expression of these apoptosis-related genes in p53-dependent and p53-independent manners. In summary, lncRNA RP11-278A23.1 contributes to colorectal cancer progression by promoting cell growth and inhibiting apoptosis, suggesting that this lncRNA may be a useful therapeutic target.

show abstract